antiangiogenesis

antiangiogenesis

Oncology Prevention of the growth of new blood vessels into a solid tumor. See angiogenesis.

antiangiogenesis

(ant?e-an?je-o-jen'e-sis) [ anti- + angiogenesis]
Prevention of the formation of new blood vessels, esp. the blood vessels that grow under the influence of malignant tumors. Agents causing antiangiogenesis include angiostatin, endostatin, tetracyclines, and paclitaxel. They are useful in the treatment of cancer. See: angiogenesis
References in periodicals archive ?
The expression of thrombospondin-1 ( TSP-1 ), an antiangiogenesis gene, showed no significant change [Figure 4]n.
The modern clinical application of the principle of angiogenesis can be divided into two main areas: antiangiogenesis therapies with which angiogenesis research began and proangiogenic therapies ([5]).
Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis.
The latter two drugs are m-TOR inhibitors, which exert antineoplastic effects through multiple mechanisms: antiangiogenesis, inhibition of cell replication, inhibition in the production of interleukin-10 (IL-10) and induction of apoptosis (18).
In vitro and animal models have suggested that the combination of lenvatinib and everolimus suppresses RTK signaling pathways, which facilitate tumor angiogenesis, at two points both upstream and down, enabling synergistic signaling inhibition for enhanced antiangiogenesis in vitro.
Los inhibidores de mTOR (mammalian target of rapamycin inhibitor) ejercen efectos antineoplasicos por multiples mecanismos: antiproliferacion, efecto antiviral, antiangiogenesis, inhibicion de la replicacion celular y de la produccion de interleucina 10 (IL-10) e induccion de apoptosis (41,42).
Thus, the biological properties of Allium plants, such as antiangiogenesis and anticancer effects, could be more possibly attributable to organosulfur ingredients.
Future treatment of the disease with antiangiogenesis therapy and vascular targeting agents is currently being evaluated in clinical trials.
Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
Melatonin inhibits tumor growth in humans and has antimitotic activity, downregulates activity of receptors with decreased estrogen binding to cells in breast cancer with enhanced immune response, free radical scavenging, and antiangiogenesis properties.
They present general principles, including the cancer genome, molecular methods, oncogenic viruses, inflammation, kinase inhibitors as anticancer drugs, antiangiogenesis agents, and an updated chapter on the hallmarks of cancer; the biology of 19 of the most common cancers, with an emphasis on how new findings have been translated for the management of patients; and a new section on genetic counseling and testing for various cancers.